Pulmonary Function in Pulmonary Sarcoidosis
-
Published:2023-10-24
Issue:21
Volume:12
Page:6701
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Yao Qian1ORCID, Ji Qiuliang2, Zhou Ying12
Affiliation:
1. Department of Clinical Research Unit, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200443, China 2. Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
Abstract
The pulmonary function test (PFT) has been widely used in sarcoidosis. It may vary due to the severity, extent, and the presence of complications of the disease. Although the PFT of most sarcoidosis patients is normal, there are still 10–30% of cases who may experience a decrease in the PFT, with a progressive involvement of lungs. Restrictive ventilatory impairment due to parenchymal involvement has been commonly reported, and an obstructive pattern can also be present related to airway involvement. The PFT may influence treatment decisions. A diffusing capacity for carbon monoxide (DLCO) < 60% as well as a forced vital capacity (FVC) < 70% portends clinically significant pulmonary sarcoidosis pathology and warrants treatment. During follow-up, a 5% decline in FVC from baseline or a 10% decline in DLCO has been considered significant and reflects the disease progression. FVC has been recommended as the favored objective endpoint for monitoring the response to therapy, and an improvement in predicted FVC percentage of more than 5% is considered effective.
Funder
National Science Foundation of Shanghai, China Science and Technology Innovation Research Project of Shanghai Science and Technology Commission, China Clinical Research Plan of SHDC, Shanghai, China National Natural Science Foundation of China, China
Reference82 articles.
1. Sève, P., Pacheco, Y., Durupt, F., Jamilloux, Y., Gerfaud-Valentin, M., Isaac, S., Boussel, L., Calender, A., Androdias, G., and Valeyre, D. (2021). Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells, 10. 2. Statement on sarcoidosis (1999). Joint statement of the american thoracic society (ATS), the european respiratory society (ERS) and the world association of sarcoidosis and other granulomatous disorders (WASOG) adopted by the ATS board of directors and by the ERS executive committee, february 1999. Am. J. Respir. Crit. Care Med., 160, 736–755. 3. Endpoints for clinical trials of sarcoidosis;Baughman;Sarcoidosis Vasc. Diffus. Lung Dis.,2012 4. Endoluminal stenosis of proximal bronchi in sarcoidosis: Bronchoscopy, function, and evolution;Chambellan;Chest,2005 5. An integrated clinicoradiological staging system for pulmonary sarcoidosis: A case-cohort study;Walsh;Lancet Respir. Med.,2014
|
|